# High levels of uric acid upregulate endothelin receptors: the role of MAPK pathways in an *in vitro* study

#### Yu-jiao Han<sup>1,2</sup>, Sen Li<sup>1</sup>

<sup>1</sup>School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China <sup>2</sup>Department of Surgical Pathology, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, China

Submitted: 25 June 2024; Accepted: 16 September 2024 Online publication: 19 November 2024

Arch Med Sci DOI: https://doi.org/10.5114/aoms/193455 Copyright © 2024 Termedia & Banach

#### Abstract

**Introduction:** Uric acid (UA) is the end product of the metabolism of purine compounds. There is overwhelming evidence linking hyperuricaemia (high levels of UA) and cerebrovascular diseases, but the effect of high levels of UA on cerebral vessels is not fully understood. The aim of this research is to clarify how UA affects the endothelin (ET) receptor in rat cerebral arteries and the related mechanism.

**Material and methods:** In an *in vitro* setting, segments of rat cerebral arteries (n = 12) were exposed to high levels of UA, either alone or in conjunction with MAPK pathway inhibitors. ET agonists were used to induce contractions that were then measured with a myograph. ET receptor expression was measured using RT-PCR (n = 6), western blot (n = 3), or immunohistochemistry (n = 3) to quantify mRNA and protein levels.

**Results:** The study revealed that high levels of UA notably increase  $ET_A$  and  $ET_B$  receptor-induced contractions and boosted the expression of ET receptors in cerebral arteries when compared to fresh or cultured alone, suggesting that UA enhances  $ET_A$  and  $ET_B$  receptors. Additionally, the up-regulation of  $ET_B$  receptors induced by UA was inhibited by the p38 inhibitor SB203580, the JNK inhibitor SP600125, and the ERK1/2 inhibitor U0126. SB203580 significantly blocked the increase in  $ET_A$  receptor-mediated contractions induced by UA and the upregulation of  $ET_A$  receptor. Neither SP600125 nor U0126 had such an effect.

**Conclusions:** High levels of UA stimulate the up-regulation of ET receptors in rat cerebral arteries *in vitro* through MAPK pathways. This study may offer novel perspectives on hyperuricaemia-associated cerebrovascular diseases.

**Key words:** hyperuricaemia, uric acid, endothelin receptor, cerebral artery, cerebrovascular disease.

#### Introduction

Uric acid (UA) is produced as the end product of oxidation of purine compounds [1]. Elevated levels of UA in the blood, known as hyperuricaemia, can lead to conditions like arthritis and gout. The incidence of hyperuricaemia worldwide has been on the rise [1]. Typically, hyperuricaemia is diagnosed when UA levels in males exceed 420  $\mu$ mol/l and in females surpass 360  $\mu$ mol/l [2]. Several research studies have confirmed a significant link between high levels of UA and cerebrovascular conditions, such as strokes in adults (both ischaemic and haemorrhagic), increasing the risk of cerebrovascular incidents and brain infarction [3]. Moreover, hyperuricaemia is

#### Corresponding author:

Sen Li School of Basic Medical Sciences Wenzhou Medical University Wenzhou, China E-mail: lzz1840@wmu.edu.cn



Creative Commons licenses: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY -NC -SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)

a standalone indicator of unfavourable results after an ischaemic stroke (mortality or disability) and subsequent cerebrovascular incidents post-stroke [4]. Elevated levels of UA are also identified as a risk factor for repeated ischaemic strokes in elderly individuals, with a connection noted between UA levels and the recurrence of strokes [5]. However, existing experimental data do not fully elucidate how high levels of UA induce cerebrovascular disorders. Prior research has shown a connection between these illnesses and abnormal hyperreactivity of the blood vessels in the brain, leading to heightened narrowing of the cerebral blood vessels. This may contribute to delayed reduction in blood flow to the brain following a lack of blood supply [6]. Upregulation of cerebral vasoconstrictor receptors can significantly enhance cerebral vasoconstriction. Therefore, it is imperative to investigate whether elevated levels of UA upregulate contractile receptors on cerebral arteries, subsequently leading to an increase in cerebrovascular hyperresponsiveness.

Endothelin-1 (ET-1), the most powerful endogenous vasoconstrictor, is chiefly secreted by endothelial cells. It binds to 2 G protein-coupled receptors,  $ET_{A}$  and  $ET_{B}$  [7]. The  $ET_{A}$  receptor, located on vascular smooth muscle cells, is linked to potent vasoconstriction [8]. Meanwhile, ET<sub>p</sub> receptors, with  $ET_{B2}$  on VSMCs causing contraction and  $ET_{R1}$  on the endothelium promoting vasodilation through nitric oxide and other vasodilators, play a dual role in vascular function [8]. It is important to mention that ET receptors can be altered by different factors like illnesses and medications [9]. Under normal physiological conditions [10], the ET<sub>R</sub> receptor mediates vasodilation; however, under pathological influences such as cerebral ischaemia [11], atherosclerosis [12, 13], hypertension [14] in humans, and subarachnoid haemorrhage [15], cerebral ischaemia [16-18], and hypertension [19–21] in rats, there is an upregulation of ET<sub>B2</sub> receptor in VSMCs resulting in significant contractions. Elevated levels of UA also pose a significant risk for cerebrovascular diseases; however, its effect on ET receptors is still unclear.

In this investigation, we study the effect of high levels of UA on ET receptors of cerebral arteries primarily to elucidate whether high levels of UA enhance the contraction mediated by ET receptors in cerebral artery and its potential mechanism. The findings from this investigation may offer novel perspectives on hyperuricaemia-associated cerebrovascular disorders.

#### Material and methods

#### Animals and reagents

Male Sprague-Dawley rats weighing 200–250 g were acquired from Beijing Vital River Laboratory Animal Technology Co., Ltd. in China. Approval for the experimental procedure was granted by the Laboratory Animal Ethics Committee at Wenzhou Medical University (No. wydw2019-0858). The study followed the National Institutes of Health Guide for Laboratory Animals (NIH Publications No. 80-23, revised 1978).

Endothelin-1 (ET-1) and sarafotoxin 6c (S6c) were acquired from China Peptides and then dissolved in a solution composed of 0.9% saline and 0.1% bovine serum albumin. MAPK pathway inhibitor SB203580 (for p38 pathway), SP600125 (for JNK pathway), U0126 (for ERK1/2 pathway), and ET<sub>B</sub> receptor antagonist BQ 788 were obtained from Selleck (Houston, Texas, USA) and Sigma (St. Louis, Missouri, USA). These compounds were dissolved in dimethyl sulfoxide (DMSO) for experimental use. Each inhibitor was added in a volume of 1  $\mu$ l to the corresponding culture wells, while an equal amount of DMSO was used as a control. Final molar concentrations in the tissue baths were displayed.

#### Artery culture

Rats were anaesthetised with CO<sub>2</sub> and sacrificed. Middle cerebral arteries were carefully separated, sliced into ring segments measuring  $1\sim 2$  mm, and then transferred to the wells of a 24-well plate containing Dulbecco's modified Eagle's medium without serum. Artery segments were divided into various experimental categories including a Fresh group, Control group (using DMSO as the solvent), UA group (200, 400, and 800 µmol/l), UA 400 µmol/l + inhibitor groups, and DMSO + inhibitor groups (n = 12 experiments per group, and only one sample was taken from each rat). The plates were incubated at 37°C in humidified 5% CO<sub>2</sub> and 95% air for 24 h.

#### Contractile function studies

A wire myograph was used to record artery contractile function. Two thin wires (40 mm in diameter) were used to thread each artery segment, which was then mounted in myograph baths containing 5 ml of Krebs solution. The segments were permitted to reach a stable state at 1.5 mN for a minimum of 1 h. Arterial activity was tested by K<sup>+</sup>-rich Krebs solution (containing 60 mmol/l KCl). Only segments that elicited reproducible responses > 1 mN to  $K^+$  were used. The selective  $ET_{_{\rm B}}$  receptor agonist, S6c, was gradually introduced at concentrations ranging from 10<sup>-7</sup> to 10<sup>-11</sup> M into the tissue baths. This allowed for a concentration-response curve specific to the  $ET_{\rm B}$  receptors. Following the inhibition of  $ET_{B}$  receptors with BQ788, the contractions elicited by ET-1 ( $10^{-7}$ – $10^{-11}$  M), which acts as an agonist for both  $ET_{R}$  and  $ET_{A}$  receptors, were assessed. These response curves were specifically attributed to the activation of ET, receptors.

#### RT-PCR

Total RNA was isolated from samples of cerebral arteries by using an E.Z.N.A. @MicroElute Total RNA Kit (R6831-02, Omega Biotech, Co. Ltd.). Reverse transcription-PCR Kits (Bioer Technology Co., Ltd., China) were utilised to synthesise cDNA from mRNA. RT-PCR was conducted with SYBRs Premix Ex TaqTM Kits from Takara, Japan, using the iQTM5 Multicolor Real-Time PCR Detection System by Bio-Rad, USA. Specific primer sequences for ET receptor genes were designed as follows: ET, receptor, forward: 50-GTC GAG AGG TGG CAA AGA CC-30; ET<sub>A</sub> receptor, reverse: 50-ACA GGG CGA AGA TGA CAA CC-30;  $ET_{B}$  receptor, forward: 50-TGACGCCACCCACTAAGACC-30; ET<sub>B</sub> receptor, reverse: 50-GGCACGGAGGAGGGAAGG-30. ET receptor gene expression levels were compared using  $\beta$ -actin mRNA as an internal reference during the measurement process and were expressed as a fold-change relative to the fresh group (n = 6 rat for each group).

#### Western blot

The protein content in cerebral artery (n = 3 rat for each group) extracts was determined using a BSA assay kit. Equal portions of 40 µg protein were electrophoresed and transferred to a nitrocellulose membrane. Following a 2-h period of incubation at ambient temperature with 5% non-fat milk to prevent non-specific binding, the membranes were exposed to primary antibodies overnight at 4°C: rabbit anti-ET<sub>4</sub> receptor (Abcam, ab85163) at 1 : 300, rabbit anti-ET<sub>R</sub> receptor (Abcam, ab262700) at 1 : 500, and mouse anti- $\beta$ -actin receptor (Santa Cruz Biotechnology, sc-47778) at 1: 2000. Following this, the membranes were exposed to secondary antibodies at room temperature for 1 h. Finally, protein bands were detected by chemiluminescent HRP substrate and captured using a computerised chemiluminescent image analysis system (Bio-Rad, Hercules, CA). Band intensity was analysed using the Imaging J System (Media Cybernetics, Bethesda, MD).

# Immunohistochemistry

Cerebral arterial tissues (n = 3 rat for each group) were prepared by fixation and dehydration, followed by cutting into slices of 10 µm thickness. Next, these sections were incubated in a 10% goat serum solution for 30 min at 37°C. Afterward, they were permitted to engage with primary antibodies at a temperature of 4°C for the duration of the night: mouse anti-ET<sub>A</sub> receptor (Santa Cruz Biotechnology, sc-518060) diluted at 1 : 500; sheep anti-ET<sub>B</sub> receptor (Abbexa, abx411769) diluted at 1 : 300. Ultimately, the tissue sections were exposed to secondary antibodies – either goat an

ti-mouse IgG H&L conjugated with FITC (Bioss, bs-0296G-FITC) or donkey anti-sheep IgG H&L (Santa Cruz Biotechnology, ab150177) – for 1 h under dark conditions. Immunoreactivity was visualised using an epifluorescence microscope (Olympus BX53, Tokyo, Japan) and photographed with a digital camera. Data analysis was performed using Image J software. Omission of primary antibodies served as a negative control.

#### Statistical analysis

Data are presented as the average value with the standard error of the mean (SEM). Statistical analyses were conducted using GraphPad Prism software version 8.2.  $E_{max}$  refers to the highest level of contraction observed, whereas pEC<sub>50</sub> represents the logarithm of the concentration of the agonist that produces half of the maximum response. Statistical comparisons were conducted using unpaired *t*-tests with Welch's correction for 2-group comparisons, or 2-way ANOVA with Bonferroni's post-test for multiple comparisons. For the analysis of multiple data sets, one-way ANOVA was conducted, followed by Dunnett's post-test. A *p*-value below 0.05 was deemed to show statistical significance.

#### Results

# Elevated UA levels increased the contraction of cerebral arteries mediated by ET receptors

In Figure 1 A, it is shown that UA at concentrations of 400 µmol/l and 800 µmol/l notably increased the contractions induced by S6c in cerebral arteries when compared to the control group (0  $\mu$ mol/l UA). The E<sub>max</sub> values were also notably higher in the UA-treated groups. In Figure 1 B, it can be observed that being exposed to 400 µmol/l UA for 24 h led to more intense ET<sub>R</sub> receptor-induced contractions in cerebral arteries when compared to exposure durations of 12 h or 48 h. In Figure 1 C, it is shown that 400 µmol/l UA notably increased the contractions to ET-1 in cerebral arteries when compared to the control group (0 µmol/l UA), resulting in a significant rise in the  $E_{max}$  values. Figure 1 D shows that exposure to UA for 24 h or 48 h induced an increase in ET, receptor-mediated contractions. Therefore, a concentration of 400 µmol/l and an exposure time of 24 h were selected as the UA culture conditions for further studies.

# High levels of UA-enhanced contraction are associated with the MAPK pathways

Inhibitors were utilised to study whether MAPK pathways are involved in UA-enhanced contractions. For  $ET_{R}$  receptors, SB203580, SP600125,



**Figure 1.** The effects of high levels of UA on concentration-contractile curves for rat cerebral artery segments, as meditated by ET receptors. **A** – Dose-dependent curve of cerebral artery constriction induced by S6c. **B** – Time-dependent curve of cerebral artery constriction induced by S6c. **C** – Dose-dependent curve of cerebral artery constriction induced by S6c. **C** – Dose-dependent curve of cerebral artery constriction induced by ET-1. **D** – Time-dependent curve of cerebral artery constriction induced by ET-1. **D** – Time-dependent curve of cerebral artery constriction induced by ET-1. D – Time-dependent curve of cerebral artery constriction induced by ET-1. D at are presented as mean  $\pm$  SEM. n = 12.  $^{\circ}p < 0.05$ ,  $^{\circ}p < 0.01$  vs. UA 0  $\mu$ mol/l (**A**, **C**);  $^{*}p < 0.05$ ,  $^{#}p < 0.05$  vs. UA 400  $\mu$ mol/l (**A**) or  $^{\circ}p < 0.05$ ,  $^{\circ}p < 0.01$  vs. Exposure to UA 400  $\mu$ mol/l (**B**, **D**)

and U0126 significantly attenuated the UA-enhanced contractions mediated by  $\text{ET}_{\text{B}}$  receptors, with a significant reduction in  $\text{E}_{\text{max}}$  values (Figures 2 A–C, p < 0.05). For  $\text{ET}_{\text{A}}$  receptors, U0126 and SP600125 did not alter the UA-enhanced contractions significantly. However, SB203580 suppressed the contractions, causing a rightward shift in the concentration-response curves, which is indicative of a notably diminished  $\text{E}_{\text{max}}$  value (Figures 2 D–F, p < 0.05).

# High levels of UA upregulate the expression of ET receptor mRNA and proteins, and are involved in the MAPK pathway

Figure 3 demonstrates that UA at concentrations of 400  $\mu mol/l$  and 800  $\mu mol/l$  stimulated

the *de novo* transcription of  $ET_{B}$  receptor mRNA. We found that exposure to UA 400 µmol/l significantly elevated the expression of  $ET_{A}$  receptor mRNA (p < 0.05, Figure 3). However, when the UA concentration was increased to 800 µmol/l, there was a non-significant downward trend in the  $ET_{A}$  receptor mRNA level.

Furthermore, as shown in Figure 4, exposure to UA at a concentration of 400 µmol/l resulted in a notable enhancement in the protein levels of  $ET_{_B}$  receptor in comparison to the control group, displaying a statistically significant variance (p <0.01). The increase in  $ET_{_B}$  receptor protein levels could be significantly reduced by using inhibitors of the MAPK pathway such as SB203580, SP600125, or U0126 (p < 0.01, Figure 4). Meanwhile, the protein expression of  $ET_{_A}$  receptor was



**Figure 2.** Effects of MAPK pathway inhibitors on UA-induced enhancement of  $\text{ET}_{\text{B}}(\mathbf{A}, \mathbf{B}, \mathbf{C})$  and  $\text{ET}_{\text{A}}(\mathbf{D}, \mathbf{E}, \mathbf{F})$  receptor-mediated concentration-contraction curves for rat cerebral arteries. The cerebral artery segments were cultured with or without UA 400 µmol/l for 24 h. In addition, the segments were cultured with UA 400 µmol/l and different MAPK inhibitors and DMSO for 24 h. S6c-induced and ET-1-induced contractions were recorded, and concentration-contraction curves for p38 inhibitor SB203580 (**A**, **D**), JNK inhibitor SP600125 (**B**, **E**), and ERK1/2 inhibitor U0126 (**C**, **F**) were constructed. Data are presented as mean ± SEM. n = 12. "p < 0.05, "p < 0.01 vs. Control (cultured with DMSO); "p < 0.01 vs. UA 400 µmol/l



**Figure 3.** Effects of UA 400  $\mu$ mol/l on ET<sub>B</sub> and ET<sub>A</sub> receptor mRNA expression in cerebral arteries. Rat cerebral arterial segments were cultured with or without UA 200, 400, and 800  $\mu$ mol/l or DMSO for 24 h. The mRNA expression levels of ET<sub>B</sub> and ET<sub>A</sub> were measured using RT-PCR and were expressed as a fold-change relative to the fresh group. Data are presented as mean ± SEM. *n* = 6. \**p* < 0.05, \*\**p* < 0.01 vs. Control (cultured with DMSO)

observed to be higher relative to the control group (p < 0.01, Figure 4). This enhancement was notably mitigated solely by the treatment with SB203580 (p < 0.01, Figure 4). Neither SP600125 nor U0126 treatments had any significant effect on the ET<sub>A</sub> receptor protein levels in both UA-exposed and control groups.

Figure 5 illustrates the application of immunohistochemistry to detect ET receptor proteins in cerebral arterial tissues, which were staining green. The negative control group were without any detectable staining for both  $\text{ET}_{\text{B}}$  and  $\text{ET}_{\text{A}}$  receptors (data not shown). The brightness level of  $\text{ET}_{\text{B}}$ receptors in cerebral arteries was discovered to be notably higher in the UA-treated group than in the control group (p < 0.01), and it was decreased by the MAPK pathway blockers SB203580, SP600125, and U0126 (p < 0.01). Likewise, the UA-treated group exhibited higher fluorescence intensity of  $\text{ET}_{\text{A}}$  receptors compared to the control group (p < 0.01). While SP600125 and U0126 did not significantly alter the fluorescence intensity in





**Figure 4.** Effects of UA 400 µmol/l on protein expression in cerebral arteries with the influence of MAPK inhibitors. Rat cerebral arterial segments were cultured with UA 400 µmol/l and p38 inhibitor SB203580 (**A**), JNK inhibitor SP600125 (**B**), ERK1/2 inhibitor U0126 (**C**), and DMSO for 24 h. The ET receptor protein expression levels were expressed relative to  $\beta$ -actin. Data are presented as mean ± SEM. n = 3. "p < 0.01 vs. Control (cultured with DMSO). ##p < 0.01 vs. UA 400 µmol/l



**Figure 5.** Immunohistology analysis of the effects of high levels of UA and MAPK inhibitors on ET receptor protein expression in cerebral arteries. Rat cerebral arterial segments were cultured with UA 400  $\mu$ mol/l and MAPK inhibitors or DMSO for 24 h. Representative images for each group ( $\mathbf{A} - ET_{\rm B}$  receptor,  $\mathbf{B} - ET_{\rm A}$  receptor). Scale bar 100  $\mu$ m, magnification ×20. Data are presented as mean ± SEM. n = 3. "p < 0.01 vs. Control. ##p < 0.01 vs. UA 400  $\mu$ mol/l



**Figure 5.** Cont. Representative images for each group the results of analyses ( $\mathbf{C} - ET_{B}$  receptor,  $\mathbf{D} - ET_{A}$  receptor). Scale bar 100 µm, magnification ×20. Data are presented as mean ± SEM. n = 3. "p < 0.01 vs. Control. "#p < 0.01 vs. UA 400 µmol/l

the UA group, SB203580 notably suppressed the UA-enhanced in  $ET_A$  receptor fluorescence intensity in cerebral arteries (p < 0.01).

# Discussion

The exact mechanisms by which hyperuricaemia causes cerebrovascular diseases remain unclear. Early researchers believed that high levels of UA could exacerbate risk factors such as dyslipidaemia, diabetes, and hypertension, contributing to the development of cerebrovascular diseases [22]. However, recent studies have proposed several mechanisms of its direct damage [23]. Herein are described the 2 main explanations for the effect of high levels of UA - one that operates without the presence of urate crystals and another that is contingent upon them [24]. In the crvstal-independent pathway, UA in its soluble form could permeate the vascular endothelium through transporters such as GLUT 9 or URATv1, thereby triggering a cascade of intracellular inflammation and oxidative stress reactions [25]. The crystallisation of UA in the body initiates once the serum UA levels surpass the solubility threshold of around 400 µmol/l [24]. In the crystal-dependent pathway, urate crystals can form, leading to the activation of NOD-like receptor family protein 3 (NLRP3) inflammasome by vascular macrophages, causing increased inflammation and collagen deposition in arteries [26]. The damage caused by elevated UA levels in patients are primarily involved in the latter mechanism. Additionally, high levels of UA can increase the expression of various factors, inducing VSMCs proliferation [27]. These mechanisms directly affect blood vessel cells and alter their function, but still fail to fully explain cerebrovascular disease associated with high levels of UA.

Researchers have observed in recent years that increasing the activity of contractile ET receptors

on cells in the cerebrovascular system could be a crucial focus for cerebrovascular events [11, 14]. Furthermore, animal models like obesity [28], subarachnoid haemorrhage [15], cerebral ischaemia [16-18], and hypertension [19-21] have shown increased expression of ET receptors. In this research, we discovered that elevated levels of UA substantially enhanced the ET receptor-induced contractions in cerebral arteries. Moreover, the expression of both mRNA and protein for ET receptors was significantly elevated in the exposure of high levels of UA. These findings indicate that elevated UA levels stimulate the upregulation of both  $ET_{R}$  and ET<sub>A</sub> receptors within the cerebral arterial system. Furthermore, the literature clearly indicates that activation of the  $\mathrm{ET}_{_{\mathrm{B2}}}$  receptor subtype in VSMCs leads to arterial constriction, whereas activation of the ET<sub>R1</sub> receptor subtype in endothelial cells induces vasorelaxation [28]. This study revealed that increasing UA levels during culturing enhanced the contractions triggered by ET receptors (both  $ET_{B1}$ and ET<sub>B2</sub> being activated by S6c). Meanwhile, the protein expression and fluorescence intensity of the  $ET_{R}$  receptors were also found to be enhanced. Taken together, these findings confirm that high levels of UA can significantly increase the number or density of  $ET_{R2}$  receptors in VSMCs.

The upregulation of ET receptors is related to several signalling pathways. In this study, we observed the relationship between the upregulation of ET receptors by high levels of UA and the MAPK signalling pathway. The MAPK signalling, composed of a series of serine/threonine kinases, is pivotal for intracellular communication triggered by external signals and governs a multitude of cellular functions [29]. This pathway is divided into 3 principal branches: p38 MAPK, JNK, and ERK1/2 pathways, each contributing to the regulation of diverse cellular responses [29]. In this study, MAPK inhibitors were observed to have no effect on ET, receptor-mediated contractions or ET receptor protein expression in the control group. However, SB203580 inhibited the UA-enhanced contractions mediated by  $ET_A$  receptors and reduced the protein expression of ET<sub>A</sub> receptors in cerebral arteries. This suggests an association between the upregulation of ET<sub>4</sub> receptors and the MAPK/ p38 pathway. However, U0126 or SP600125 had no effect on ETA receptor-induced contraction or ETA receptor protein levels in cerebral arteries, suggesting that the ERK1/2 or JNK pathways do not play a role in this increase. Further, SB386023, SB203580, and U0126 did not affect contractions mediated by ET<sub>B</sub> receptors or ET<sub>B</sub> receptor protein expression in control groups. Also, the protein expression of ET<sub>B</sub> receptor in cerebral arteries was reduced by all 3 inhibitors, leading to a decrease in UA-enhanced contractions mediated by ET<sub>R</sub> receptors. These data imply a connection between the increase in  $ET_{\rm B}$  receptors and the activation of all 3 MAPK pathways. Clearly, there is still much to explore regarding how high levels of UA play a role in impacting the MAPK/ET receptor pathways upstream and downstream.

In conclusion, high levels of UA up-regulate ET receptors in *in vitro* rat cerebral arteries. The up-regulation of  $ET_B$  receptors is associated with the ERK1/2, JNK, and p38 MAPK pathways, while the upregulation of  $ET_A$  receptors is linked to the p38 pathway. Although further *in vivo* experiments are necessary, this study offers novel perspectives on hyperuricaemia-associated cerebrovascular diseases.

#### Funding

This research was funded by Natural Science Foundation of Zhejiang Province, grant number LQ20H020002.

# Ethical approval

The research protocol was approved by the Ethics Committee of Wenzhou Medical University (Ethic Approval Number: wydw2019-0858) and complied with the National Institute of Health Guide (National Institute of Health Publications No. 80-23, Revised 1978).

#### **Conflict of interest**

The authors declare no conflict of interest.

#### Reference

- 1. Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol 2020; 11: 582680.
- 2. Hao Y, Li H, Cao Y, et al. Uricase and horseradish peroxidase hybrid CaHPO(4) nanoflower integrated with

transcutaneous patches for treatment of hyperuricemia. J Biomed Nanotechnol 2019; 15: 951-65.

- 3. Padda J, Khalid K, Padda S, et al. Hyperuricemia and its association with ischemic stroke. Cureus 2021; 13: e18172.
- 4. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.
- 5. Zhu HY, Zhao SZ, Zhang ML, et al. Elevated serum uric acid increases the risk of ischemic stroke recurrence and its inflammatory mechanism in older adults. Front Aging Neurosci 2022; 14: 822350.
- 6. Johansson S, Povlsen GK, Edvinsson L. Expressional changes in cerebrovascular receptors after experimental transient forebrain ischemia. PLoS One 2012; 7: e41852.
- 7. Houde M, Desbiens L, D'Orleans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. Adv Pharmacol 2016; 77: 143-75.
- Schneider MP, Boesen EI, Pollock DM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007; 47: 731-59.
- 9. Huang B, Zhang W, Wei L, Chen S, Wang T, Fu R. Resveratrol down-regulates endothelin type B receptors in vascular smooth muscle cells via Sirt1/ERK1/2/NF-small ka, CyrillicB signaling pathways. Eur J Pharmacol 2018; 840: 44-9.
- 10. Shoemaker LN, Haigh KM, Kuczmarski AV, et al. ET(B) receptor-mediated vasodilation is regulated by estradiol in young women. Am J Physiol Heart Circ Physiol 2021; 321: H592-8.
- 11. Bhalla S, Leonard MG, Briyal S, Gulati A. Distinct alteration in brain endothelin A and B receptor characteristics following focal cerebral ischemia in rats. Drug Res (Stuttg) 2016; 66: 189-95.
- Pernow J, Bohm F, Johansson BL, Hedin U, Ryden L Enhanced vasoconstrictor response to endothelin-B-receptor stimulation in patients with atherosclerosis. J Cardiovasc Pharmacol 2000; 36: S418-20.
- Bohm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 674-9.
- 14. Nilsson D, Wackenfors A, Gustafsson L, et al. Increased ET(A) and ET(B) receptor contraction in the left internal mammary artery from patients with hypertension. J Hum Hypertens 2008; 22: 226-9.
- Povlsen GK, Johansson SE, Larsen CC, Samraj AK, Edvinsson L Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhage. BMC Neurosci 2013; 14: 34.
- 16. Touzani O, Galbraith S, Siegl P, McCulloch J. Endothelin-B receptors in cerebral resistance arterioles and their functional significance after focal cerebral ischemia in cats. J Cereb Blood Flow Metab 1997; 17: 1157-65.
- Stenman E, Malmsjo M, Uddman E, Gido G, Wieloch T, Edvinsson L. Cerebral ischemia upregulates vascular endothelin ET(B) receptors in rat. Stroke 2002; 33: 2311-6.
- Henriksson M, Stenman E, Vikman P, Edvinsson L. Protein kinase C inhibition attenuates vascular ETB receptor upregulation and decreases brain damage after cerebral ischemia in rat. BMC Neurosci 2007; 8: 7.
- Brakch N, Abdel-Sayed S, Allemandou F, et al. Renal endothelin receptor type B upregulation in rats with low or high renin hypertension. J Hypertens 2004; 22: 1797-803.

- Dai X, Galligan JJ, Watts SW, Fink GD, Kreulen DL Increased O2\*- production and upregulation of ETB receptors by sympathetic neurons in DOCA-salt hypertensive rats. Hypertension 2004; 43: 1048-54.
- 21. Mirabito Colafella KM, Neves KB, Montezano AC, et al. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats. Cardiovasc Res 2020; 116: 1779-90.
- 22. Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta 2018; 484: 150-63.
- 23. Albu A, Para I, Porojan M. Uric acid and arterial stiffness. Ther Clin Risk Manag 2020; 16: 39-54.
- 24. Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension 2018; 72: 582-4.
- 25. Mishima M, Hamada T, Maharani N, et al. Effects of uric acid on the NO production of HUVECs and its restoration by urate lowering agents. Drug Res (Stuttg) 2016; 66: 270-4.
- 26. Gicquel T, Robert S, Loyer P, et al. IL-1beta production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages. FASEB J 2015; 29: 4162-73.
- 27. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8.
- 28. Baretella O, Chung SK, Xu A, Vanhoutte PM. Endothelial overexpression of endothelin-1 modulates aortic, carotid, iliac and renal arterial responses in obese mice. Acta Pharmacol Sin 2017; 38: 498-512.
- 29. Zhang Y, Edvinsson L, Xu CB. Up-regulation of endothelin receptors induced by cigarette smoke--involvement of MAPK in vascular and airway hyper-reactivity. ScientificWorldJournal 2010; 10: 2157-66.